Xtant Medical (NYSEAMERICAN:XTNT) Announces Quarterly Earnings Results

Xtant Medical (NYSEAMERICAN:XTNT) announced its quarterly earnings results on Tuesday. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.05), FiscalAI reports. The firm had revenue of $23.03 million during the quarter, compared to the consensus estimate of $24.88 million. Xtant Medical had a negative net margin of 10.17% and a negative return on equity of 22.28%.

Here are the key takeaways from Xtant Medical’s conference call:

• Revenue and guidance declined: Q2 revenue fell to $23.0 million from $24.8 million on a pro forma basis, primarily due to weakness in legacy orthobiologics and amnio products. Xtant reduced full-year revenue guidance to $99 million–$103 million from $101 million–$105 million.
• Profitability weakened materially: Gross margin fell to 57.9% from 68.6%, while the company reported a $9.4 million net loss and a $2.7 million adjusted EBITDA loss, partly reflecting the $5 million Dilon fee, lower production efficiency, and inventory charges.
• HEMOBLAST® integration is progressing: The company recognized approximately $1.5 million of Q2 HEMOBLAST® revenue and expects transactional volume to exceed $1 million per month on a gross basis, with substantially all future sales expected to flow through Xtant’s contracts and distribution network.
• Expanded commercial reach and new products support future growth: Xtant integrated 17 Dilon salespeople and expanded its broader commercial team to more than 25 representatives, while reporting strong early traction for Trivium™ Shaped. Management expects these investments and cross-selling opportunities to accelerate biologics growth in the second half of 2026.

Xtant Medical Price Performance

NYSEAMERICAN:XTNT traded down $0.01 during mid-day trading on Thursday, hitting $0.30. The company’s stock had a trading volume of 41,803 shares, compared to its average volume of 145,269. The stock has a fifty day moving average of $0.43 and a 200-day moving average of $0.51. Xtant Medical has a fifty-two week low of $0.27 and a fifty-two week high of $0.95. The company has a market capitalization of $42.08 million, a price-to-earnings ratio of -3.75 and a beta of -0.13. The company has a current ratio of 3.34, a quick ratio of 1.64 and a debt-to-equity ratio of 0.17.

Analyst Ratings Changes

Separately, BTIG Research reissued a “buy” rating and set a $1.00 target price on shares of Xtant Medical in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, Xtant Medical presently has a consensus rating of “Buy” and an average target price of $1.00.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of XTNT. Jane Street Group LLC bought a new position in shares of Xtant Medical in the second quarter worth about $26,000. Wiregrass Investment Management LLC bought a new stake in shares of Xtant Medical during the fourth quarter valued at approximately $81,000. Mink Brook Asset Management LLC grew its stake in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Xtant Medical by 28.8% in the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after purchasing an additional 205,945 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after purchasing an additional 104,159 shares during the last quarter. Institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.